In the present study, beating iPSC-CMs were generated from healthy controls and HCM patients with DD. Micropatterned iPSC-CMs from HCM patients showed impaired diastolic function, as evidenced by prolonged relaxation time, decreased relaxation rate, and shortened diastolic sarcomere length. 
Introduction
Hypertrophic cardiomyopathy (HCM) is characterized by abnormal thickening of the ventricular wall and increased risk of arrhythmia, sudden death, and heart failure. 1 Many familial HCM cases are caused by mutations in sarcomere genes. 2 Diastolic dysfunction (DD), manifested by slowed or incomplete ventricular relaxation during diastole, is a prominent clinical feature in HCM patients. 3 Without treatment, DD can progress into heart failure, which leads to significant morbidity and mortality. [4] [5] [6] However, the underlying cellular mechanisms of DD in HCM are not well understood, which greatly impedes the development of specific and effective therapies.
To study the mechanisms of DD in HCM, various animal models (from rodents to large animals) and disease-induction methods have been used. 7, 8 However, significant interspecies differences make it difficult to extrapolate animal results to humans, and there has been no investigation of DD mechanism using human-origin cardiomyocytes. Human induced pluripotent stem cell (iPSC) technology has enabled patient-specific disease modelling of various cardiovascular diseases, [9] [10] [11] [12] [13] which offered a unique opportunity to establish human cell modelling platforms of DD in HCM.
Here, we generated induced pluripotent stem cell-derived cardiomyocyte (iPSC-CM) models of DD that carry different mutations in three most commonly involved sarcomeric proteins in familial HCM [i.e. myosin heavy chain 7 (MYH7), myosin binding protein C3 (MYBPC3), and cardiac troponin T2 (TNNT2)]. These iPSC-CM models of DD recapitulated impaired diastolic function at the singlecell level. Based on various functional assays, we demonstrated that both elevated diastolic Ca 2þ and increased myofilament Ca 2þ sensitivity contribute to the cellular mechanisms of DD in HCM iPSCCMs. To rescue impaired relaxation, we rebalanced Ca 2þ homeostasis in HCM iPSC-CMs with optimized doses of Ca 2þ blockers (verapamil, diltiazem) and late Na þ current blockers (ranolazine, eleclazine), all of which improved cellular diastolic performance. Our research provides a patient-specific iPSC-CM platform for modelling and elucidating cellular mechanisms of DD in HCM.
Methods
Peripheral blood mononuclear cell isolation and reprogramming HCM patients with DD and healthy control individuals were recruited based on the most updated guidelines. 14, 15 All recruitment and consenting procedures were carried out according to Stanford Institutional Review Board (IRB) approved protocol. Patient-specific iPSC lines were generated through over-expression of 4-Yamanaka factors in peripheral blood mononuclear cells (Supplementary material online, Method).
Maintenance and differentiation of induced pluripotent stem cells
Human iPSCs were maintained in Essential 8 TM Medium (Gibco V R , Life Technology) and were differentiated into beating cardiomyocytes using monolayer differentiation protocol 16 (Supplementary material online, Method).
Cell micropatterning on the hydrogel
The single iPSC-CMs were micropatterned according to the adult CMlike morphology on 10 kPa polyacrylamide hydrogel, which was precoated with Matrigel (Corning, 1:10 dilution in PBS) in a defined geometry relying on the stencil-based microfabrication techniques, as described previously. 17 
Statistical analysis
All data are presented as mean ± standard deviation. The statistical analysis was performed using SigmaPlot 12.5 and GraphPad Prism 8 (Supplementary material online, Method).
Results
Human induced pluripotent stem cellderived cardiomyocytes carrying hypertrophic cardiomyopathy mutations exhibit diastolic dysfunction
We recruited six familial HCM mutation carriers who exhibited clinical records of diastolic dysfunction (DD) (Supplementary material online, Figure S1A ). These patients carry MYH7 R663H (n = 2), MYBPC3 V321M (n = 1), MYBPC3 V219L (n = 1), and TNNT2 R92W (n = 2) mutations. We also recruited one HCM patient without the DD phenotype, and who carried a mutation in MYBPC3 (c.2905þ1G>A). Healthy individuals (n = 2) without HCM mutations were used as wild type controls (Supplementary material online, Table S1 ). Peripheral blood mononuclear cells of all groups were isolated and reprogrammed to iPSCs. The quality of all derived iPSC lines was tested by immunostaining of pluripotent markers such as Sox2, Nanog, SSEA-4, and Oct4 (Supplementary material online, Figure S1B ). Human iPSC-CMs were differentiated using standard monolayer methods. 16 The purity of iPSC-CMs was >90% as evaluated by fluorescence-activated cell sorting (FACS) and
Translational perspective
Diastolic dysfunction (DD) is commonly associated with hypertrophic cardiomyopathy (HCM). DD can progress into diastolic heart failure, the major cause of morbidity and mortality due to HCM. However, the cellular pathogenic mechanisms of DD remain unclear, and thus an effective drug therapy has yet to be developed. Figure S1C and D).
To measure the diastolic function, beating iPSC-CMs from each group were dissociated into single cells and seeded on a micropatterned matrix with a 1:7 width/length ratio ( Figure 1A) . 17 After recovery, micropatterned iPSC-CMs exhibited well-aligned sarcomere structures along the longitudinal axis ( Figure 1A , bottom panel). To mark the sarcomere structure in live cells, a GFP-human actin fusion protein was expressed in the iPSC-CMs ( Figure 1B) . Sarcomere shortening was recorded using confocal microscopy by line scanning along the myofilaments ( Figure 1B and C). Our results show that the diastolic sarcomere length is significantly shorter in all three HCM iPSC-CM groups (1.788 ± 0.113, 1.844 ± 0.111, and 1.720 ± 0.130 mm for MYH7, MYBPC3, and TNNT2 groups, respectively) compared with the Ctrl cells (1.985 ± 0.138 mm) ( Figure 1D ). Interestingly, the maximum relaxed sarcomere lengths of Ctrl and HCM iPSC-CMs, measured in Ca 2þ -free Tyrode's solution, were comparable ( Figure   1E ), indicating that the shorter diastolic sarcomere length in HCM iPSC-CMs was not due to structural remodelling of the sarcomere. Hypertrophic cardiomyopathy iPSC-CMs also exhibited a decreased maximum relaxation rate and prolonged normalized relaxation duration when compared with Ctrl iPSC-CMs ( Figure 1F and G), whereas the beating rate and maximum contraction velocity remained unchanged (Supplementary material online, Figure S2A -D). These results suggest that iPSC-CM model exhibits a distinct DD phenotype at the single-cell level. Isogeneic induced pluripotent stem cell lines confirmed the pathogenicity of TNNT2 R92W mutation in diastolic dysfunction
To confirm the pathogenicity of the sarcomeric mutations in the observed DD phenotype, we next generated isogenic Ctrl and diseased iPSC lines of TNNT2 R92W mutation using CRISPR/Cas9 (Supplementary material online, Figure S5A -E). 18 Functional assays showed that both heterozygous and homozygous mutation introduction led to elevated diastolic Ca 2þ and prolonged Ca 2þ transient decay time. Moreover, the mutation-carrying isogenic iPSC-CMs For each group, data were generated from two different iPSC lines and three batches of differentiation. Figure 3H ).
Short-term b-adrenergic challenge exaggerates diastolic dysfunction in hypertrophic cardiomyopathy induced pluripotent stem cell-derived cardiomyocytes b-adrenergic signalling is the most important lusitropic regulation in the intact heart. 21 To further elevated, the abnormal arrhythmia-like Ca 2þ transients were also significantly increased in ISO-treated HCM iPSC-CMs ( Figure  4D ). In sarcomere shortening measurement, the beating rates of Ctrl and HCM iPSC-CMs were significantly accelerated by ISO ( Figure 4F ). However, HCM iPSC-CMs consistently showed shorter diastolic and peak sarcomere lengths, and slower relaxation velocity after ISO treatment compared with Ctrl iPSC-CMs ( Figure 4G -H, Supplementary material online, Figure S7C ). Moreover, both normalized relaxation and contraction duration 90 were further prolonged in ISO treated HCM iPSC-CMs compared with untreated HCM cells ( Figure 4I , Supplementary material online, Figure S7D ). Collectively, these results strongly suggest that short-term b-adrenergic challenge exaggerate DD in HCM iPSC-CMs. 22, 23 In addition, late Na þ current (I NaL ) has been reported to play a role in the pathogenesis of DD, and late Na þ channel blockers improved diastolic function in both HF patient CMs and DD animal models. 24, 25 However, the therapeutic effects of Ca 2þ current (I Ca ) and I NaL inhibition in DD are not clear.
To better understand the therapeutic mechanisms of these agents, we treated HCM iPSC-CMs with Ca 2þ blockers (verapamil and diltiazem) and late Na þ channel blockers (ranolazine and eleclazine) ( Figure 5A , Supplementary material online, Figure S8A ). The drug doses (10-200 nM for verapamil, 10-500 nM for diltiazem, 1-10 mM for ranolazine, and 200 nM to 1 mM for eleclazine) were applied according to previous studies and clinical prescriptions (Supplementary material online, Figure S8A ). 11 Our results show that the treatment at an optimized dose of these drugs have restored diastolic [Ca 2þ ] i and transient decay time in HCM iPSC-CMs ( Figure 5B and C, Supplementary material online, Figure S8B -D). Sarcomere shortening measurements also confirmed that optimized dose of Ca 2þ and late Na þ blockers partially recovered diastolic sarcomere lengths ( Figure 5D , Supplementary material online, Figure S8E ), increased relaxation rate, and reduced relaxation duration in HCM iPSC-CMs ( Figure 5 and F, Supplementary material online, Figure S8F -G). Sacubitril/valsartan (neprilysin inhibitor and angiotensin receptor blockers) has been shown to be effective for treating HF patients with DD. 26 However, when tested in our DD model, sacubtril/valsartan has no significant effect, probably because our single-cell iPSC-CM model does not reflect the signalling complexity that exists at the tissue/systemic level (Supplementary material online, Figure S8A -G).
Improve the viability of hypertrophic cardiomyopathy induced pluripotent stem cell-derived cardiomyocytes by targeting long-term Ca 2þ overload
To understand the mechanisms of diastolic Ca 2þ overload in HCM iPSC-CMs, we quantified the mRNA expression of key Ca 2þ handling proteins. qPCR results show increased Cav1.2, MYH7, and stress marker (NPPA, NPPB) and decreased MYH6, Casq2, and Cav3 mRNA levels in HCM iPSC-CMs compared with Ctrl iPSC-CMs ( Figure 6A , Supplementary material online, Figure S9A ). Our results also showed that transient receptor potential cation channels (TRPCs) 1 and 3, the main cardiac TRPC subtypes, were both increased in HCM iPSC-CMs (Supplementary material online, Figure  S9B , Figure 6E Figure   S9F ), while HCM iPSC-CMs showed higher TRPC-dependent SOCE amplitude and rising rate compared with the Ctrl group (Supplementary material online, Figure S9G and H). To validate the role of TRPCs during the pathogenesis of DD, we also treated HCM Figure S8A -G).
A recent study reported that CaMKIId activation contributes to diastolic Na þ and Ca 2þ overload and impaired diastolic function. 29 Indeed, our western blot analysis showed that CaMKIId autophosphorylation was significantly up-regulated by 308 ± 42% in HCM iPSC-CMs compared with Ctrl iPSC-CMs, which was partially suppressed by I Ca or I NaL blockers ( Figure 6B and I NaL inhibition ( Figure 6C and D) . Long-term ISO treatment also activated apoptotic signalling, as both Ctrl and HCM iPSC-CMs exhibited increased caspase activity ( Figure 6E and F) , while b-blockers repressed the pro-apoptotic effect. Interestingly, I Ca and I NaL blockers elicited significant pro-survival effects only in HCM iPSCCMs, presumably because diastolic Ca 2þ handling was only altered in HCM iPSC-CMs. Taken together, these results suggest that by rebalancing Ca 2þ homeostasis, I Ca and I NaL blockers exert beneficial effects on HCM iPSC-CMs both in short-term functional performance and long-term signalling integrity.
Discussion
As a growing cause of congestive heart failure, DD has been widely modelled and investigated in various systems, including rodents, canine, swine, and newly isolated or cultured cardiomyocytes. 7, 8 However, few studies have been based in human cardiomyocytes, and none are patient-specific. Here, we established a novel platform to investigate DD using patient-specific HCM iPSC-CMs. Working with and elevate diastolic active force development and basal tension. As previous reports showed that pressure overload in heart leads to increased expression of TRPC channels that promote cardiac hypertrophy, 27 ,28 TRPC up-regulation may contribute to DD pathogenesis in HCM iPSC-CM model. Indeed, qPCR profiling and SOCE measurements confirmed that the expression and activity of LTCC, and TRPC1/3 were up-regulated in HCM iPSC-CMs. Increased Ca 2þ influx through these channels promoted diastolic Ca 2þ overload, and impaired the relaxation of HCM iPSC-CMs, which was partially rescued by TRPC3 specific blocker Pyr3. One important outcome of long-term diastolic Ca 2þ overload in HCM iPSC-CMs is the activation of CaMKIId ( Figure 6B ). Chronic CaMKIId activation are commonly seen in heart failure. However, our gain-and loss-of-function study based on iPSC-CM models has clearly confirmed the critical role of CaMKIId activation during the pathogenesis of DD, which exacerbates the Ca 2þ and Na þ disturbances, induces apoptosis, and influences transcriptional regulation. 36 This finding indicate two possible working mechanisms through which I Ca or I NaL inhibition relieve symptoms in patient with DD: [22] [23] [24] [25] (i) I Ca and I NaL blockers limit overall Ca 2þ and Na þ influx, which stabilize the diastolic and improve the ability of NCX to extrude Ca 2þ ; (ii) Figure S11 ).
One limitation of our study is that our single-cell iPSC-CM model cannot capture tissue or systemic level contributions of increased wall thickness and extracellular matrix changes, 37 which may also contribute to DD in HCM. Other factors, such as changes in myocardium stiffness, conduction blockade, aging, and increased fibrosis cannot be recapitulated in our current model. The morphological and physiological differences of iPSC-CMs compared with adult ventricle cardiomyocytes also pose challenges to clinical applications. 38 Future studies incorporating engineered heart tissues may enable further systematic investigations of DD at a more integrated level. In summary, we report a human iPSC-based cellular model of HCM that recapitulates DD at the single-cell level. Functional imaging analysis highlighted diastolic Ca 2þ overload and enhanced myofilament Ca 2þ sensitivity, both of which contribute to the increased diastolic tension and impaired relaxation seen in HCM iPSC-CMs. Moreover, perturbed Ca 2þ homeostasis in HCM iPSC-CMs exacerbates the DD, providing a window of potential therapeutic intervention by I Ca , I NaL , and CaMKII inhibitors which may restore diastolic function and prevent apoptosis during long-term adrenergic stress. Our findings here augment our knowledge of the pathogenesis in DD and the mechanisms underlying the beneficial effects of currently available drugs. Moreover, our work suggests that the iPSC-CM model provide a suitable platform for mutation-specific mechanistic studies and drug screening for DD in HCM.
Supplementary material
Supplementary material is available at European Heart Journal online.
